Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 5, 2015, Pages 1097-1107

  Patel, Jaina M ^a   Kim, Min Chul ^b,c   Vartabedian, Vincent F ^a   Lee, Yu Na ^b   He, Sara ^a   Song, Jae Min ^d   Choi, Hyo Jick ^e   Yamanaka, Satoshi ^a   Amaram, Nikhil ^a   Lukacher, Anna ^a   Montemagno, Carlo D ^e   Compans, Richard W ^a   Kang, Sang Moo ^b   Selvaraj, Periasamy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

^d Sungshin Women's University   (South Korea)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

GM CSF; GPI anchored proteins; Influenza; Protein transfer; Virus like particles

Indexed keywords

IMMUNE SYSTEM; MACROPHAGES; MAMMALS; NANOPARTICLES; VACCINES; VIRUSES;

GM-CSF; GPI-ANCHORED PROTEIN; INFLUENZA; PROTEIN TRANSFER; VIRUS-LIKE PARTICLES;

PROTEINS;

CD40 LIGAND; FATTY ACID BINDING PROTEIN; FLAGELLIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NANOPARTICLE; UNCLASSIFIED DRUG; VIRUS LIKE NANOPARTICLE; GLYCOSYLPHOSPHATIDYLINOSITOL; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; VIRUS ANTIBODY;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BONE MARROW; CONTROLLED STUDY; CROSS PROTECTION; DNA MODIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS; LUNG; MOUSE; NONHUMAN; PROTEIN TRANSPORT; SPLEEN; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CHEMISTRY; CHO CELL LINE; CRICETULUS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VIRION;

MUS; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CHO CELLS; CRICETULUS; FEMALE; GLYCOSYLPHOSPHATIDYLINOSITOLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLUENZA VACCINES; MICE, INBRED BALB C; NANOPARTICLES; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VIRION;

EID: 84931041097     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.02.008     Document Type: Article

References (40)

1. Kirchenbaum G.A., Ross T.M. Eliciting broadly protective antibody responses against influenza. Curr Opin Immunol 2014, 28:71-76.
2. Ulmer J.B., Valley U., Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol 2006, 24(11):1377-1383.
3. Kang S.M., Song J.M., Quan F.S., Compans R.W. Influenza vaccines based on virus-like particles. Virus Res 2009, 143(2):140-146.
4. Lopez-Macias C. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic. Hum Vacc Immunother 2012, 8(3):411-414.
5. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9(10):1149-1176.
6. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40(1):60-65.
7. Cubas R., Zhang S., Kwon S., Sevick-Muraca E.M., Li M., Chen C., et al. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 2009, 32(2):118-128.
8. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38(5):1404-1413.
9. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(19):3871-3878.
10. Kang S.M., Yoo D.G., Lipatov A.S., Song J.M., Davis C.T., Quan F.S., et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009, 4(3):e4667.
11. Song J.M., Hossain J., Yoo D.G., Lipatov A.S., Davis C.T., Quan F.S., et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 2010, 405(1):165-175.
12. Skountzou I., Quan F.S., Gangadhara S., Ye L., Vzorov A., Selvaraj P., et al. Incorporation of glycosylphosphatidylinositol-anchored granulocyte-macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol 2007, 81(3):1083-1094.
13. Wang B.Z., Quan F.S., Kang S.M., Bozja J., Skountzou I., Compans R.W. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008, 82(23):11813-11823.
14. Zhang R., Zhang S., Li M., Chen C., Yao Q. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine 2010, 28(31):5114-5127.
15. Kaczmarczyk S.J., Sitaraman K., Young H.A., Hughes S.H., Chatterjee D.K. Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A 2011, 108(41):16998-17003.
16. Ranka R., Petrovskis I., Sominskaya I., Bogans J., Bruvere R., Akopjana I., et al. Fibronectin-binding nanoparticles for intracellular targeting addressed by B. burgdorferi BBK32 protein fragments. Nanomedicine 2013, 9(1):65-73.
17. Haynes J.R. Influenza virus-like particle vaccines. Expert Rev Vaccines 2009, 8(4):435-445.
18. Nagarajan S., Selvaraj P. Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res 2002, 62(10):2869-2874.
19. Poloso N.J., Nagarajan S., Bumgarner G.W., Selvaraj P. Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine 2001, 19:2029-2038.
20. Poloso N.J., Nagarajan S., Mejia-Oneta J.M., Selvaraj P. GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine. Mol Immunol 2002, 38(11):803-816.
21. Carpen O., Pallai P., Staunton D.E., Springer T.A. Association of intercellular adhesion molecule-1 (ICAM-1) with actin-containing cytoskeleton and alpha-actinin. J Cell Biol 1992, 118(5):1223-1234.
22. McHugh R.S., Ahmed S.N., Wang Y.C., Sell K.W., Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A 1995, 92(17):8059-8063.
23. Nagarajan S., Selvaraj P. Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination. Vaccine 2006, 24(13):2264-2274.
24. Quan F.S., Sailaja G., Skountzou I., Huang C., Vzorov A., Compans R.W., et al. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine 2007, 25(19):3841-3850.
25. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223(1):77-92.
26. Reed L.J., Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
27. Cimino A.M., Palaniswami P., Kim A.C., Selvaraj P. Cancer vaccine development: protein transfer of membrane-anchored cytokines and immunostimulatory molecules. Immunol Res 2004, 29:231-240.
28. Poloso N., Nagarajan S., Bumgarner G.W., Zampell J.C., Selvaraj P. Designer cancer vaccines made easy: protein transfer of immunostimulatory molecules for use in therapeutic tumor vaccines. Front Biosci 2001, 6:D760-D775.
29. Patel J.M., Vartabedian V.F., Selvaraj P. Lipid-mediated cell surface engineering. Micro- and Nanoengineering of the Cell Surface Micro and Nano Technologies 2014, 121-141. Elsevier Inc., USA. J.K.W. Zhao (Ed.).
30. Low M.G., Saltiel A.R. Structural and functional roles of glycosyl-phosphatidylinositol in membranes. Science 1988, 239(4837):268-275.
31. Le Tallec D., Doucet D., Elouahabi A., Harvengt P., Deschuyteneer M., Deschamps M. Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum Vaccin 2009, 5(7):467-474.
32. Chen Q., Lai H. Plant-derived virus-like particles as vaccines. Hum Vacc Immunother 2013, 9(1):26-49.
33. Ludwig C., Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007, 18(6):537-545.
34. Lefeber D.J., Benaissa-Trouw B., Vliegenthart J.F., Kamerling J.P., Jansen W.T., Kraaijeveld K., et al. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect Immun 2003, 71(12):6915-6920.
35. Kodihalli S., Kobasa D.L., Webster R.G. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000, 18(23):2592-2599.
36. Win S.J., Ward V.K., Dunbar P.R., Young S.L., Baird M.A. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol Cell Biol 2011, 89(6):681-688.
37. El Sahly H.M., Davis C., Kotloff K., Meier J., Winokur P.L., Wald A., et al. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis 2012, 205(5):703-712.
38. Hendrikx L.H., Berbers G.A., Veenhoven R.H., Sanders E.A., Buisman A.M. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4years of age: effect of vaccine antigen content. Vaccine 2009, 27(47):6530-6536.
39. Jing X., Phy K., Li X., Ye Z. Increased hemagglutinin content in a reassortant 2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing donor A/Puerto Rico/8/34 virus transmembrane and stalk domains. Vaccine 2012, 30(28):4144-4152.
40. Wong S.S., Webby R.J. Traditional and new influenza vaccines. Clin Microbiol Rev 2013, 26(3):476-492.